Navigation Links
Protalix BioTherapeutics, Inc. Receives Approval from the FDA to,Initiate a Phase III Clinical Trial of prGCD

Protalix BioTherapeutics, Inc.

Protalix's proprietary technology is based on its plant cell culture and bioreactor system, which provides an effective and scaleable cell system for industrial production of recombinant biopharmaceuticals. Protalix is pursuing advanced clinical studies for its enzyme therapy for Gaucher Disease and intends to advance additional recombinant biopharmaceutical drug development programs. The Company believes its plant-based expression has significant advantages over more traditional mammalian and bacterial expression technology with respect to patient safety, cost and scalability.

Safe Harbor Statement

To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, the inherent risks and uncertainties in developing drug platforms and products of the type we are developing; delays in our preparation and filing of applications for regulatory approval; delays in the approval or potential rejection of any applications we file with the FDA, or other health regulatory authorities; lack of progress of our research and development (including the results of clinical trials being conducted by us); obtaining on a timely basis sufficient patient enrollment in our clinical trials; the impact of development of competing therapies and/or technologies by other companies; our ability to obtain additional financings required to fund our research programs; our
'"/>




Page: 1 2 3

Related medicine technology :

1. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
2. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
3. Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
4. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
5. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:3/27/2015)... /CNW Telbec/ - Russell Williams , President of ... welcomes the 2015-2016 Quebec Budget, noting the fiscal discipline ... biopharmaceutical industry. However, the association is concerned about the ... the government,s intent to strive for a balanced budget ... Quebec,s economic development is encouraging," ...
(Date:3/27/2015)... 2015 The Temple Health & Bioscience District (THBD) ... building at 1802 South First St. in the Temple Medical ... City of Temple to receive funding ... Central Texas Veterans Health Care System, the new facility will ... stage biotechnology and life science companies. ...
(Date:3/27/2015)... -- Zimmer Holdings, Inc. (NYSE and SIX: ZMH) is launching ... Available in both small (6mm) and large ... System from Zimmer is a modular system that offers surgeons ... XtraFix System allows surgeons to eliminate steps, as well ... in saved time, costs and overall team effort. ...
Breaking Medicine Technology:Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 2Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 3Temple Health & Bioscience District Relocates, Offers Office And Lab Space To Biotech Companies 2Zimmer Debuts New Modular External Fixation System 2Zimmer Debuts New Modular External Fixation System 3
... June Issue of Circulation , , SILVER SPRING, ... (Nasdaq: UTHR ) and Eli Lilly and ... results of a pivotal 16-week study showing that a ... exercise capacity and improved time to clinical worsening in ...
... Health (TFAH) and the Robert Wood Johnson Foundation (RWJF) ... that Americans rank prevention as the most important health ... prevention programs to reduce disease and keep people healthy. ... Greenberg Quinlan Rosner Research and Public Opinion Strategies, 70 ...
Cached Medicine Technology:Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily 2Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily 3Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily 4Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily 5Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily 6New Poll Finds Disease Prevention is Top Priority for Americans in Health Reform 2New Poll Finds Disease Prevention is Top Priority for Americans in Health Reform 3New Poll Finds Disease Prevention is Top Priority for Americans in Health Reform 4New Poll Finds Disease Prevention is Top Priority for Americans in Health Reform 5
(Date:3/28/2015)... 2015 Pitching speed, player’s height, and pitching ... and elbow injuries, according to new research released today at ... Specialty Day. , “Our findings indicate that a 10 inch ... likelihood of a history of injury, a 10 mile per ... likelihood of a history of injury, and playing for more ...
(Date:3/28/2015)... How best to treat and recover ... orthopaedic medicine. While diagnostic hip injections are commonly performed ... etiology, research presented today at the American Orthopaedic Society ... that pain relief from this diagnostic injection may not ... “Our study looked to assess if the amount of ...
(Date:3/28/2015)... Early surgery may not be the best ... injuries, according to new research from Tripler Army Medical ... Society for Sports Medicine’s ( AOSSM ) Specialty Day, ... was not performed. , The final study group focused ... 17 receiving non-surgical therapy. Of the non-surgery group, 8 ...
(Date:3/28/2015)... San Francisco, California (PRWEB) March 28, 2015 ... search for original 1960's Who psychedelic concert posters. The Who ... Flushing, New York on August 2, 1968. According to Hawley, ... 1969 playing many concert halls and college campuses. Perhaps the ... their performance with Jim Morrison and the Doors on August ...
(Date:3/28/2015)... March 28, 2015 Aureus Medical ... staffing, including physical therapy jobs, has announced that ... Ohio Physical Therapy Association Annual Conference to be ... Downtown Hotel in Columbus, OH. , The ... and exhibits with products and services. , ...
Breaking Medicine News(10 mins):Health News:Researchers Highlight Shoulder and Elbow Injury Possibility in Youth Players 2Health News:Pain Injections for Hip Arthroscopy Patients May Not Predict Surgical Outcomes 2Health News:For Type V AC Joint Injuries, Early Surgery May Not Be the Best Approach 2Health News:Avid Collector from Vintage Rock Posters, Inc. Announces His Search For Original 1960's Who Psychedelic Concert Posters. 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the Ohio Physical Therapy Association Annual Conference 2
... study of women with an unusual form of breast cancer, ... making the case for a particular combination of treatments to ... 2009 issue of the Annals of Surgical Oncology , ... (DMS), and his colleaguesamong them Wendy Wells, M.D., a professor ...
... 27, 2009Two University of Rhode Island associate professors, biophysicists ... that can detect cancerous tumors and deliver treatment to ... thereby significantly reducing side effects. The URI couple has ... years. In addition, a number of health care and ...
... of Physical Medicine and Rehabilitation (AAPM&R) awarded Jay ... Medicine and Rehabilitation, the Physiatric Association of Spine, ... Lectureship. The award recognizes an individual who has ... or research. Dr. Smith is the first to ...
... interventional radiologist one Friday night three years ago when he ... Hospital & Clinics. He was asked to attend to a ... to the emergency room with massive blood clots in her ... what happened," said Kuo, assistant professor of radiology at the ...
... less of a mystery, study finds. , TUESDAY, Oct. 27 ... the progression of cancer by stimulating a pathway inside cells. ... treatment of cancer, which has been linked to alcohol use ... connected to colon and breast cancer, although it,s not known ...
... ... solution , ... City, CA (PRWEB) October 27, 2009 -- Ziosoft®, Inc. ( http://www.ziosoftinc.com ) a leader ... leading suppliers of PACS and teleradiology systems, today announced that they have signed an ...
Cached Medicine News:Health News:URI research couple's method targets cancerous tumors 2Health News:URI research couple's method targets cancerous tumors 3Health News:URI research couple's method targets cancerous tumors 4Health News:Stanford study recommends change in treating pulmonary embolisms 2Health News:Stanford study recommends change in treating pulmonary embolisms 3Health News:Stanford study recommends change in treating pulmonary embolisms 4Health News:Mapping the Link Between Alcohol, Cancer 2Health News:Ziosoft Announces Agreement with Imaging & Medical Information Technology to Distribute Ziosoft's 3D Advanced Visualization Software in Turkey 2Health News:Ziosoft Announces Agreement with Imaging & Medical Information Technology to Distribute Ziosoft's 3D Advanced Visualization Software in Turkey 3
... Screening: The Procleix System has added ... the nation's blood supply. It utilizes innovative ... and a unique nucleic acid amplification technique ... can simultaneously detect the presence of HIV-1 ...
... Reveal Rapid HIV-1 Antibody Test (Reveal Test) ... test detects antibodies in human serum or ... the body in response to HIV infection. ... proprietary flow-through membrane technology, and is comprised ...
The Becton™ Colles Fracture Plate has proven clinical outcomes and has excellent patient acceptance compared to external fixation. It provides a cost effective treatment option through a simple...
X-Hair Trephines...
Medicine Products: